ARS Pharmaceuticals (SPRY) Long-Term Deferred Tax (2023 - 2025)

ARS Pharmaceuticals has disclosed Long-Term Deferred Tax across 3 years of filings, most recently posting $73.4 million for Q4 2025.

• Long-Term Deferred Tax for Q4 2025 came in at $73.4 million, up 99.13% year-over-year; the trailing twelve-month figure through Dec 2025 was $73.4 million (up 99.13% YoY), and the FY2025 annual result was $73.4 million, up 99.13% from the prior year.
• Long-Term Deferred Tax came in at $73.4 million for Q4 2025 at ARS Pharmaceuticals, up from $36.9 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $73.4 million in Q4 2025 to a low of $29.0 million in Q4 2023.
• The 3-year median for Long-Term Deferred Tax is $36.9 million (2024), against an average of $46.4 million.
• Across the five-year window, Long-Term Deferred Tax rose 26.92% in 2024 and soared 99.13% in 2025, its largest moves.
• ARS Pharmaceuticals' Long-Term Deferred Tax stood at $29.0 million in 2023, then rose by 26.92% to $36.9 million in 2024, then jumped by 99.13% to $73.4 million in 2025.
• The last three Long-Term Deferred Tax figures came in at $73.4 million (Q4 2025), $36.9 million (Q4 2024), and $29.0 million (Q4 2023), per Business Quant data.